Latest Stories
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The company expects the full year’s revenue to be around $825 million, close to analysts’ estimates. Its non-GAAP profit of $0.49 per share was 10.4% above analysts’ consensus estimates.
Option Care Health (NASDAQ:OPCH) Posts Q4 CY2025 Sales In Line With Estimates
Alternate site health provider Option Care Health (NASDAQ:OPCH) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.8% year on year to $1.47 billion. On the other hand, the company’s full-year revenue guidance of $5.9 billion at the midpoint came in 1.4% below analysts’ estimates. Its non-GAAP profit of $0.46 per share was in line with analysts’ consensus estimates.
Sotera Health Company’s (NASDAQ:SHC) Q4 CY2025: Beats On Revenue
Healthcare services company Sotera Health (NASDAQ:) announced better-than-expected revenue in Q4 CY2025, with sales up 4.6% year on year to $303.4 million. The company’s full-year revenue guidance of $1.24 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 7% above analysts’ consensus estimates.
DigitalOcean (NYSE:DOCN) Beats Q4 CY2025 Sales Expectations, Growth To Accelerate Next Year
Cloud computing platform DigitalOcean (NYSE:DOCN) announced better-than-expected revenue in Q4 CY2025, with sales up 18.3% year on year to $242.4 million. Guidance for next quarter’s revenue was better than expected at $249.5 million at the midpoint, 0.5% above analysts’ estimates. Its non-GAAP profit of $0.44 per share was 15.5% above analysts’ consensus estimates.
Enviri’s (NYSE:NVRI) Q4 CY2025 Sales Top Estimates
Steel and waste handling company Enviri (NYSE:NVRI) beat Wall Street’s revenue expectations in Q4 CY2025, but sales were flat year on year at $556.4 million. Its non-GAAP loss of $0.17 per share was 25% above analysts’ consensus estimates.
Bowhead Specialty (NYSE:BOW) Surprises With Q4 CY2025 Sales
Specialty insurance company Bowhead Specialty Holdings (NYSE:BOW) announced better-than-expected revenue in Q4 CY2025, with sales up 27.1% year on year to $151.7 million. Its GAAP profit of $0.44 per share was 2.2% below analysts’ consensus estimates.
Shoals (NASDAQ:SHLS) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops 10.8%
Solar energy systems company Shoals (NASDAQ:SHLS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 38.6% year on year to $148.3 million. On top of that, next quarter’s revenue guidance ($130 million at the midpoint) was surprisingly good and 9.6% above what analysts were expecting. Its non-GAAP profit of $0.10 per share was 28.4% below analysts’ consensus estimates.
Armstrong World (NYSE:AWI) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Ceiling and wall solutions company Armstrong World Industries (NYSE:AWI) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.6% year on year to $388.3 million. On the other hand, the company’s full-year revenue guidance of $1.77 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.61 per share was 4% below analysts’ consensus estimates.
AdaptHealth (NASDAQ:AHCO) Surprises With Q4 CY2025 Sales
Healthcare services provider AdaptHealth Corp. (NASDAQ:AHCO) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.2% year on year to $846.3 million. The company’s full-year revenue guidance of $3.48 billion at the midpoint came in 1% above analysts’ estimates. Its GAAP loss of $0.76 per share was significantly below analysts’ consensus estimates.
First Watch (NASDAQ:FWRG) Posts Q4 CY2025 Sales In Line With Estimates
Breakfast restaurant chain First Watch Restaurant Group (NASDAQ:FWRG) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 20.2% year on year to $316.4 million. Its GAAP profit of $0.24 per share was significantly above analysts’ consensus estimates.